Original language | English |
---|---|
Pages (from-to) | iv238-iv255 |
Journal | Annals of Oncology |
Volume | 29 |
DOIs | |
State | Published - 1 Oct 2018 |
Access to Document
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Annals of Oncology, Vol. 29, 01.10.2018, p. iv238-iv255.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Hepatocellular carcinoma
T2 - ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
AU - Vogel, A.
AU - Cervantes, A.
AU - Chau, I.
AU - Daniele, B.
AU - Llovet, J.
AU - Meyer, T.
AU - Nault, J. C.
AU - Neumann, U.
AU - Ricke, J.
AU - Sangro, B.
AU - Schirmacher, P.
AU - Verslype, C.
AU - Zech, C. J.
AU - Arnold, D.
AU - Martinelli, E.
N1 - Funding Information: AV has received honoraria for talks and advisory boards from Bayer, Roche, Lilly, Bristol-Myers Squibb, Merck Sharp & Dohme, AstraZeneca, Eisai, Novartis and Ipsen; AC has provided consulting and advisory services for Merck Serono, Amgen, Servier, Roche, Lilly, Novartis, Takeda and Astellas and has received research support from Roche, Merck Serono, Servier, Beigene and Astellas; IC has reported being a member of the advisory boards of Eli-Lilly, Bristol-Myers Squibb, MSD, Bayer, Roche, Merck-Serono, Five Prime Therapeutics and Astra-Zeneca and has received research funding from Eli-Lilly, Janssen-Cilag, Sanofi Oncology, Merck-Serono and honorarium from Eli-Lilly; BD has received honoraria or consultation fees from Bayer, Bristol-Myers Squibb, MSD, Merck KGaA, Ipsen, Eisai and Lilly; JL has received consultancy fees from Bayer, Bristol-Myers Squibb, Incyte, Lilly, Eisai, Celsion, Glycotest, Ipsen, Merck and Exelixis and research support from Incyte, Bayer, Bristol-Myers Squibb and Eisai; TM has received consulting fees from Bristol-Myers Squibb, Bayer, Eisai, Ipsen, Merck, BTG and Beigene; UN has given presentations for Merck, Amgen, Roche, Grünenthal and Bayer on topics other than HCC; JR has received consulting fees and research grants from Bayer Healthcare and Sirtex Medical; BS has received consulting and/or lecture fees from Adaptimmune, AstraZeneca, Bayer, Bristol-Myers Squibb, BTG, Onxeo, Sirtex and Terumo; PS has reported being a member of advisory board and has received grants from Novartis and Bristol-Myers Squibb; CV has received consultancy fees and re-19. search funding from Bayer, Sirtex, Novartis and Ipsen; CJZ has received honoraria for lectures and advisory boards by Bayer Healthcare; DA has received honoraria for consultancy from Roche, Merck Serono, Bayer Healthcare, Servier, BTG, Terumo, Sanofi Oncology and Eli Lilly; EM has received honoraria for lecture and advisory boards for Roche, Amgen, Servier and Sanofi; JCN has reported no conflicts of interest.
PY - 2018/10/1
Y1 - 2018/10/1
UR - http://www.scopus.com/inward/record.url?scp=85054346991&partnerID=8YFLogxK
U2 - 10.1093/annonc/mdy308
DO - 10.1093/annonc/mdy308
M3 - Article
C2 - 30285213
AN - SCOPUS:85054346991
SN - 0923-7534
VL - 29
SP - iv238-iv255
JO - Annals of Oncology
JF - Annals of Oncology
ER -